Experience of point-of-care HbA1c testing in the English National Health Service Diabetes Prevention Programme: an observational study.
diabetes mellitus, type 2
point-of-care systems
primary prevention
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
19
06
2020
revised:
09
09
2020
accepted:
21
09
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
To report the observations of point-of-care (POC) glycated hemoglobin (HbA1c) testing in people with non-diabetic hyperglycemia (NDH; HbA1c 42-47 mmol/mol (6.0%-6.4%)), applied in community settings, within the English National Health Service Diabetes Prevention Programme (NHS DPP). A service evaluation assessing prospectively collected national service-level data from the NHS DPP, using data from the first referral received in June 2016-October 2018. Individuals were referred to the NHS DPP with a laboratory-measured HbA1c in the NDH range and had a repeat HbA1c measured at first attendance of the program using one of three POC devices: DCA Vantage, Afinion or A1C Now+. Differences between the referral and POC HbA1c and the SD of the POC HbA1c were calculated. The factors associated with the difference in HbA1c and the association between POC HbA1c result and subsequent attendance of the NHS DPP were also evaluated. Data from 73 703 participants demonstrated a significant mean difference between the referral and POC HbA1c of -2.48 mmol/mol (-0.23%) (t=157, p<0.001) with significant differences in the mean difference between devices (F(2, 73 700)=738, p<0.001). The SD of POC HbA1c was 4.46 mmol/mol (0.41%) with significant differences in SDs between devices (F(2, 73 700)=1542, p<0.001). Participants who were older, from more deprived areas and from Asian, black and mixed ethnic groups were associated with smaller HbA1c differences. Normoglycemic POC HbA1c versus NDH POC HbA1c values were associated with lower subsequent attendance at behavioral interventions (58% vs 67%, p<0.001). POC HbA1c testing in community settings was associated with significantly lower HbA1c values when compared with laboratory-measured referrals. Acknowledging effects of regression to the mean, we found that these differences were also associated with POC method, location, individual patient factors and time between measurements. Compared with POC HbA1c values in the NDH range, normoglycemic POC HbA1c values were associated with lower subsequent intervention attendance.
Identifiants
pubmed: 33318069
pii: 8/2/e001703
doi: 10.1136/bmjdrc-2020-001703
pmc: PMC7737024
pii:
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JV is the national clinical director for Diabetes and Obesity at NHS England and is the Clinical Lead for the Healthier You: NHS Diabetes Prevention Programme. EB is the Head of Health Intelligence (diabetes) for Public Health England and leads analysis of the Diabetes Prevention Programme. CB is the primary care advisor to the NHS Diabetes Programme. BY is clinical lead of the National Diabetes Audit for England and Wales and a Trustee of Diabetes UK. KK was chair of the Programme Development Group for the National Institute for Health and Care Excellence (NICE) public health guidance on type 2 diabetes: prevention in people at high risk (NICE PH38). KK is also codirector of the Leicester Diabetes Centre, and one of the programme providers, Ingeus UK Ltd, provide interventions based on the type 2 Diabetes Prevention Programme developed by LDC. NJW was Chair of the Programme Development Group for NICE public health guidance on Type 2 diabetes prevention: population and community-level interventions (NICE PH35). JS represents Public Health England on the NHS England Diabetes Programme Board. SON is the clinical director at Diabetes UK. MS is primary investigator for the NDPS programme. WGJ was chair of the IFCC-WG on Haemoglobin A1c Standardisation and of the IFCC-TF.
Références
Clin Chem. 2018 Aug;64(8):1183-1192
pubmed: 29921723
Diabet Med. 2018 Apr;35(4):513-518
pubmed: 29266374
Endocrinol Nutr. 2016 Oct;63(8):387-96
pubmed: 27481442
BMC Public Health. 2017 Jan 6;17(1):31
pubmed: 28056894
Scand J Clin Lab Invest. 2000 Aug;60(5):349-56
pubmed: 11003254
Sci Rep. 2018 Apr 19;8(1):6240
pubmed: 29674706
Clin Chem. 2011 Apr;57(4):568-76
pubmed: 21368238
Br J Gen Pract. 2010 Mar;60(572):e98-104
pubmed: 20202351
Clin Chem. 2014 Aug;60(8):1062-72
pubmed: 24865164
PLoS One. 2018 Feb 23;13(2):e0191316
pubmed: 29474501
Diabet Med. 2012 Nov;29(11):1350-7
pubmed: 22957983
Clin Chem Lab Med. 2017 Feb 1;55(2):167-180
pubmed: 27658148
Diabetes Care. 2020 Jan;43(1):152-160
pubmed: 31719054
Diabetes Care. 2011 Jun;34(6):e61-99
pubmed: 21617108
Diabetes Res Clin Pract. 2015 Jun;108(3):e49-52
pubmed: 25819481
J Diabetes Sci Technol. 2018 Jul;12(4):753-761
pubmed: 29619895
Pharm World Sci. 2006 Jun;28(3):171-9
pubmed: 17004016
Clin Chem. 2010 Jan;56(1):44-52
pubmed: 19926777
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Clin Chem. 2013 Dec;59(12):1790-801
pubmed: 23958846
Crit Rev Clin Lab Sci. 2017 Nov - Dec;54(7-8):471-494
pubmed: 29169287
Clin Chem. 2015 May;61(5):752-9
pubmed: 25737535
Diabetes Res Clin Pract. 2007 Mar;75(3):339-47
pubmed: 16884811